1. Home
  2. Companies
  3. PER
  4. Material Events

Percheron Therapeutics (ASX:PER) — Material Events

ASX:PER · 10 articles in the last 12 months · 100% assessed

Click a band to jump to that tier

Significant 8 articles Notable 2 articles Not Assessed 0 articles
Major ≥90 Significant 75–89 Notable 50–74 Routine <50 Not assessed
Significant Score 75–89
8
$2.3 Million Placement Secures Funding for Percheron's AML TrialMedium
$2.3 Million Placement to Fund AML Clinical Trial
1 Sept 2026 ·Capital Raising ·85
Percheron Advances HMBD-002 with Positive Phase I Data and Phase II PlansMedium
Percheron reports positive phase I data for HMBD-002, advances phase II trial plans, and strengthens leadership
31 Oct 2025 ·Quarterly Activities Report and Appendix 4C ·85
Percheron Therapeutics Unveils Promising Phase I Data, Sets Stage for Modular Phase II TrialMedium
Percheron Therapeutics reports positive phase I HMBD-002 data, plans modular phase II trial in 2026
30 Jan 2026 ·Quarterly Activities Report and Appendix 4C ·85
Not Assessed Low Score, or missing data
0

No articles in this tier for the last 12 months.